NCT02888054View on ClinicalTrials.gov

Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 30, 2016

Primary Completion Date

October 18, 2016

Study Completion Date

February 1, 2017

Conditions
Healthy
Interventions
DRUG

lesinurad/allopurinol 200/300 FDC tablet

DRUG

lesinurad 200 mg

DRUG

allopurinol 300 mg

Trial Locations (1)

78744

Austin

Sponsors
All Listed Sponsors
lead

Ardea Biosciences, Inc.

INDUSTRY

NCT02888054 - Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence | Biotech Hunter | Biotech Hunter